
Novartis’ serelaxin was once thought to be the major hope for its cardiovascular pipeline – analysts projected it to become …
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
Tridem begins phase Ib trial of Parkinson’s disease vaccine
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns

